Michael Henry

Michael Henry is a board-certified pediatric hematologist/oncologist with over 20 years of experience, specializing in benign and malignant hematology and histiocytic disorders. Michael has a strong track record in early phase clinical trial development and has published numerous peer-reviewed manuscripts. They served as the Director of the Hematology/Oncology Fellowship Training Program and the Early Drug Development Program at Phoenix Children's Hospital and currently holds the position of Clinical Research Medical Director for blinatumomab at Amgen. Michael is also recognized as an Associate Professor of Clinical Pediatrics at the University of Arizona College of Medicine - Phoenix.